Is a combination of gemcitabine and docetaxel effective in advanced urothelial carcinoma?
Published Sep 1, 2005 · M. Stöckle, J. Lehmann
Nature Clinical Practice Urology
0
Citations
0
Influential Citations
Abstract
DESIGN Patients with locally advanced, recurrent, or metastatic stage IV transitional cell carcinoma (TCC) of the urothelial tract were enrolled in a nonrandomized phase II study between May 2000 and April 2002. Only those aged ≤75 years, with no prior history of chemotherapy or who had received adjuvant chemotherapy (excluding gemcitabine) ≥12 months previously, were eligible. Exclusion criteria included an ECOG PERFORMANCE STATUS of ≥3, central nervous system metastases, creatinine clearance of <50 ml/min, and insufficient levels of white blood cells, neutrophils, or platelets.
Study Snapshot
Key takeawayA combination of gemcitabine and docetaxel is effective in advanced urothelial carcinoma, particularly in patients aged 75 years with no prior history of chemotherapy.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.